Koroner yavaş akım olan hastalarda pentraksin-3 düzeyi artmıştır

AMAÇ: Koroner yavaş akım YKA , anjiyografisinde normal koroner arterlere sahip olup opak maddenin koronerlerin distaline geç ulaşması ile karakterizedir. YKA’ın inflamasyon ve yüksek duyarlıklı C reaktif protein hs-CRP gibi inflamatuvar belirteçler ile ilişkisi bilinmektedir. Pentraksin-3 PTX-3 , yeni bir akut faz reaktanı olup CRP gibi pentraksin ailesinin bir üyesidir. Biz bu çalışmada YKA hastalarında PTX-3 düzeyini araştırdık.YÖNTEMLER: Çalışmaya YKA saptanan 25 hasta ve koroner arter hastalığı KAH olan 26 hasta alındı. Yavaş koroner akım ve KAH tanısı koroner anjiyografi ile konuldu. Kardiyoloji polikliniğine başvurmuş iskemik bulguların gözlenmediği 24 sağlıklı birey kontrol grubu olarak alındı. Tüm grubun PTX-3 ve hs-CRP çalışıldıBULGULAR: KYA grubundaki hastaların PTX-3 ve hs-CRP seviyesi kontrol grubuna göre daha yüksekti sırasıyla 0.52 ± 0.2 ng/ml ve 0.20 ±0.08 ng/ml, p

Anahtar Kelimeler:

Koroner yavaş akım, hs-CRP, inflamasyon, Pentraksin-3

Increased pentraxin-3 level in patients with slow coronary flow

OBJECTIVE: Slow coronary flow SCF is defined as late opacification in the epicardial coronary artery without significant stenosis on the coronary angiographic images. The association between SCF and inflammation and inflammatory markers such as high sensitivity-C reactive protein hs-CRP is well known. Pentraxin-3 PTX-3 , a new acute phase reactant, is a member of pentraxine family like hs-CRP. We investigated the association between PTX-3 and hs-CRP in patients with SCF.METHODS: The study included 25 patients with SCF and 26 patients with coronary artery disease CAD whose diagnoses were made by coronary angiography. The control group consisted of 24 healthy subjects admitted cardiology outpatient clinic without any sign of ischemia. From the all study population PTX-3 and hs-CRP levels were measured.RESULTS: The SCF group had significantly increased PTX-3 and hs-CRP levels than the control group 0.52 ± 0.2 ng/ml vs 0.20 ±0.08 ng/ml, p

Keywords:

Slow coronary flow, Pentraxin-3, hs-CRP,

PDF

___

Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries--a new angiographic finding. Am Heart J 1972; 84: 66-71.
Gibson CM, Cannon CP, Daley WL, Dodge JT, Jr., Alexander B, Jr., Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879-88.
Goel PK, Gupta SK, Agarwal A, Kapoor A. Slow coronary flow: a distinct angiographic subgroup in syndrome X. Angiology 2001; 52: 507-14.
Kaski JC, Tousoulis D, Galassi AR, McFadden E, Pereira WI, Crea F, Maseri A. Epicardial coronary artery tone and reactivity in patients with normal coronary arteriograms and reduced coronary flow reserve (syndrome X). J Am Coll Cardiol 1991; 18: 50-54.
Pekdemir H, Cin VG, Cicek D, Camsari A, Akkus N, Doven O, Parmaksiz HT. Slow coronary flow may be a sign of diffuse atherosclerosis. Contribution of FFR and IVUS. Acta Cardiol 2004; 59: 127-33.
Ari H, Ari S, Erdogan E, Tiryakioglu O, Huysal K, Koca V, Bozat T. The effects of endothelial dysfunction and inflammation on slow coronary flow. Turk Kardiyol Dern Ars 2010; 38: 327-33.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
Li JJ, Qin XW, Li ZC, Zeng HS, Gao Z, Xu B, Zhang CY, Li J. Increased plasma C-reactive protein and interleukin-6 concentrations in patients with slow coronary flow. Clin Chim Acta 2007; 385: 43-47.
Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-38.
Karakas MF, Buyukkaya E, Kurt M, Motor S, Akcay AB, Karakas E, Buyukkaya S, Sen N. Serum Pentraxin-3 Levels Are Associated with the Severity of Metabolic Syndrome. Med Princ Pract 2012: (inpress)
Salio M, Chimenti S, De Angelis N, Molla F, Maina V, Nebuloni M, Pasqualini F, Latini R, Garlanda C, Mantovani A. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008; 117: 1055-64.
Karakas MF, Buyukkaya E, Kurt M, Motor S, Akcay AB, Buyukkaya S, Karakas E, Bilen P, Sen N. Serum Pentraxin 3 Levels Are Associated With the Complexity and Severity of Coronary Artery Disease in Patients With Stable Angina Pectoris. J Investig Med 2012: (inpress)
Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323: 27-36.
Li JJ. Inflammation in coronary artery diseases. Chin Med J (Engl) 2011; 124: 3568-75.
Li JJ, Xu B, Li ZC, Qian J, Wei BQ. Is slow coronary flow associated with inflammation? Med Hypotheses 2006; 66: 504-08.
Madak N, Nazli Y, Mergen H, Aysel S, Kandaz M, Yanik E, Cekdemir D, Tavli T. Acute phase reactants in patients with coronary slow flow phenomenon. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 2010; 10: 416-20.
Sen N, Ozlu MF, Basar N, Ozcan F, Gungor O, Turak O, Malcok O, Cagli K, Maden O, Erbay AR, Demir AD. Relationship between elevated serum gamma- glutamyltransferase activity and slow coronary flow. Turk Kardiyol Dern Ars 2009; 37: 168-73.
Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2010; 28: 157-83.
Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, Latini R. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 2006; 45: 326-30.
Maugeri N, Rovere-Querini P, Slavich M, Coppi G, Doni A, Bottazzi B, Garlanda C, Cianflone D, Maseri A, Mantovani A, Manfredi AA. Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction. J Immunol 2011; 187: 970-79.
Sen N, Basar N, Maden O, Ozcan F, Ozlu MF, Gungor O, Cagli K, Erbay AR, Balbay Y. Increased mean platelet volume in patients with slow coronary flow. Platelets 2009; 20: 23-28.